




Fig. 1




Fig. 2




Fig. 3




Fig. 4

CHO-K1 (Human CD19)




Fig. 5




Fig. 6




Fig. 7




Fig. 8




Fig. 9




Fig. 10




Fig. 11




Fig. 12




Fig. 13




Fig. 14




Fig. 15




Fig. 16




Fig. 17




Fig. 18




Fig. 19A




Fig. 19B




Fig. 20A




Fig. 20B




Fig. 21

Competition study of CD3 on cyno blood
Mean MFI




Fig. 22A

Competition study of CD20 on cyno blood
Mean MFI




Fig. 22B

Blood




Fig. 23A




Fig. 23B

Bone marrow




Fig. 24A

Bone marrow




Fig. 24B

Mesenteric lymph node




Fig. 25A




Fig. 25B

Mandibular lymph node




Fig. 26A

Mandibular lymph node




Fig. 26B

Spleen




Fig. 27A

Spleen




Fig. 27B

Blood




Fig. 28A

Blood

After treatment




Fig. 28B

Bone marrow




Fig. 29A

Bone marrow

After treatment




Fig. 29B





Fig. 30A

Mesenteric lymph node




Fig. 30B

Mandibular lymph node




Fig. 31A




Fig. 31B

Spleen




Fig. 32A

Spleen




Fig. 32B




Fig. 33A




Fig. 33B




Fig. 34A




Fig. 34B




Fig. 35




Fig. 36A




Fig. 36B




Fig. 37A




Fig. 37B




Fig. 38




Fig. 39




Fig. 40




Fig. 41




Fig. 42





Fig. 43



Fig. 44

**Fig. 45**




Fig. 46


**Fig. 47**



Fig. 48




Fig. 49




Fig. 50



Fig. 51




Fig. 52




Fig. 53




Fig. 54




Fig. 55

DLS




Fig. 56




Fig. 57




Fig. 58




Fig. 59




Fig. 60




Fig. 61




Fig. 62




Fig. 63




Fig. 64




Fig. 65




Fig. 66




Fig. 67




Fig. 68




Fig. 69




Fig. 70




Fig. 71




Fig. 72A




Fig. 72B




Fig. 73




Fig. 74




Fig. 75

- W333021
- TNS-488 (CD3xCD19)
- Mosunetuzumab (CD3xCD20)
- Glofitamab (CD3xCD20)
- Negative Control




Fig. 76




Fig. 77




Fig. 78A




Fig. 78B




Fig. 79